Abstract
BackgroundInterstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept and rituximab are the preferred disease-modifying antirheumatic drugs (DMARDs) for RA-ILD [1-4]. However, progression of ILD despite...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
